Maven Securities LTD Buys New Shares in Adaptive Biotechnologies Corporation (NASDAQ:ADPT)
Maven Securities LTD bought a new stake in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 52,500 shares of the company’s stock, valued at approximately $2,513,000. Adaptive Biotechnologies accounts for 1.7% of Maven Securities LTD’s holdings, making the stock its 25th largest position.
A number of other institutional investors have also modified their holdings of the business. Hudock Capital Group LLC bought a new stake in shares of Adaptive Biotechnologies in the 2nd quarter valued at $62,000. AGF Investments Inc. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth approximately $121,000. GSA Capital Partners LLP acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth approximately $290,000. Landscape Capital Management L.L.C. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth approximately $316,000. Finally, SG Americas Securities LLC bought a new position in Adaptive Biotechnologies in the second quarter worth approximately $724,000. Hedge funds and other institutional investors own 62.83% of the company’s stock.
In other Adaptive Biotechnologies news, insider Nancy Louise Hill bought 11,200 shares of the firm’s stock in a transaction dated Monday, July 1st. The stock was purchased at an average cost of $20.00 per share, with a total value of $224,000.00. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, major shareholder Viking Global Performance Llc bought 250,000 shares of the stock in a transaction dated Monday, July 1st. The shares were acquired at an average price of $20.00 per share, for a total transaction of $5,000,000.00. The disclosure for this purchase can be found here. Insiders bought a total of 262,200 shares of company stock worth $5,244,000 in the last 90 days.
Adaptive Biotechnologies (NASDAQ:ADPT) last released its quarterly earnings results on Tuesday, August 13th. The company reported ($1.23) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($1.08). The company had revenue of $22.10 million for the quarter, compared to analyst estimates of $19.39 million. The business’s revenue was up 90.5% compared to the same quarter last year. On average, equities research analysts predict that Adaptive Biotechnologies Corporation will post -0.63 earnings per share for the current year.
A number of equities research analysts have commented on ADPT shares. BTIG Research initiated coverage on Adaptive Biotechnologies in a research note on Tuesday, July 23rd. They issued a “buy” rating and a $46.00 price objective for the company. Guggenheim assumed coverage on Adaptive Biotechnologies in a research report on Monday, July 22nd. They set a “buy” rating and a $47.00 target price on the stock. JPMorgan Chase & Co. started coverage on Adaptive Biotechnologies in a report on Monday, July 22nd. They issued an “overweight” rating and a $45.00 target price on the stock. William Blair began coverage on shares of Adaptive Biotechnologies in a research report on Monday, July 22nd. They issued an “outperform” rating for the company. Finally, Goldman Sachs Group initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, July 22nd. They set a “neutral” rating and a $32.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $43.00.
Adaptive Biotechnologies Company Profile
Adaptive Biotechnologies Corporation develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer research questions that inform current and future clinical trials, as well as to discover new prognostic and diagnostic signals.
Read More: Different Types of Derivatives
Receive News & Ratings for Adaptive Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptive Biotechnologies and related companies with MarketBeat.com's FREE daily email newsletter.